.png){kind=icon}
.png){kind=icon}
Return
In vivo CRISPR base editing for treatment of Huntington’s disease
.png){kind=icon}
OA
AI
S
M
D
K
A
N
D
P
D
M
A
A
A
N
G
G
M
J
W
D
C
S
T
P
DOI：10.1038/s41551-026-01747-y.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Huntington’s disease (HD) is a fatal neurodegenerative disorder caused by an expanded CAG repeat within exon 1 of the huntingtin (HTT) gene, resulting in a mutant protein that drives neuronal dysfunction and loss. A key event in the pathogenesis of HD is proteolytic cleavage of mutant HTT, which generates aggregation-prone N-terminal fragments that contribute to toxicity. Strategies that prevent this process thus hold therapeutic potential. Here we develop CRISPR base editors that generate proteolysis-resistant HTT isoforms by disrupting the splice acceptor of HTT exon 13, an exon that encodes critical proteolytic cleavage sites implicated in N-terminal fragment production. When delivered to the striatum of an HD rodent model, these editors reduced HTT fragment formation, decreased aggregation, improved functional deficits and attenuated brain atrophy. Collectively, these results demonstrate the potential of base editing and splice-site modulation to mitigate mutant HTT toxicity in HD. CRISPR base editors were used to create proteolysis-resistant huntingtin isoforms to reduce the production of aggregation-prone protein fragments that contribute to neurotoxicity and to mitigate toxicity in mouse models of Huntington’s disease.
Journal
IF:
26.6
Papers:
1.7K
Citations:
2.0W
Organization
Cited Papers